Podcasts about NIF

In this episode of Valley of Depth, we sit down with Xcimer Energy's cofounders, Conner Galloway and Alexander Valys, to unpack one of the boldest bets in fusion: resurrecting a Cold War-era laser technology to build the fastest, most scalable path to commercial fusion power.Xcimer has raised over $100 million to bring its inertial confinement fusion system to life, starting with LPK, a high-powered prototype laser built in just four months, and progressing toward Vulcan, a full-scale, ignition-class reactor designed for the grid. We also discuss:Why excimer lasers are making a comebackWhat Xcimer learned from building LPK in just four monthsThe Phoenix-to-Vulcan roadmap for commercial fusionLessons from NIF's ignition milestone and its limitsThe case for fusion as infrastructure, not just scienceHow Xcimer is positioning itself in a crowded fusion landscape…and much, more. • Chapters •00:00 – Intro01:24 – Payload Pro02:06 – Recent changes in fusion03:29 – Commercial fusion and perceptions on the tech05:18 – Founding story of Xcimer06:51 – Common approaches to fusion today08:48 – Was the National Ignition Facility (NIF) the catalyst to start Xcimer?12:22 – Convincing investors to invest $100m into Xcimer13:34 – What is NIF's goal right now and can it produce electricity?18:04 – Why hasn't the private sector solved the fusion problem?20:25 – Xcimer progress report23:07 – Xcimer's roadmap for the next bigger machine24:41 – Coming up with Athena25:33 – Addressing neutron damage29:54 – The biggest unknown for Xcimer32:29 – Who are Xcimer's first customers35:03 – Cost per megawatt per hour to be competitive37:23 – How much of Xcimer's supply chain is being verticalized38:48 – Vaporizing a missile with a laser41:27 – Other fusion companies Alex and Connor admire44:28 – What inspires a founder or engineer to pursue less proven fusion methods?47:28 – What drives Alex and Connor to keep on going?49:02 – First commercial Xcimer fusion plant • Show notes •Xcimer's website — https://xcimer.energy/Mo's socials — https://twitter.com/itsmoislamPayload's socials — https://twitter.com/payloadspace / https://www.linkedin.com/company/payloadspaceIgnition's socials — https://twitter.com/ignitionnuclear /  https://www.linkedin.com/company/ignition-nuclear/Tectonic's socials  — https://twitter.com/tectonicdefense / https://www.linkedin.com/company/tectonicdefense/Valley of Depth archive — Listen: https://pod.payloadspace.com/ • About us •Valley of Depth is a podcast about the technologies that matter — and the people building them. Brought to you by Arkaea Media, the team behind Payload (space), Ignition (nuclear energy), and Tectonic (defense tech), this show goes beyond headlines and hype. We talk to founders, investors, government officials, and military leaders shaping the future of national security and deep tech. From breakthrough science to strategic policy, we dive into the high-stakes decisions behind the world's hardest technologies.Payload: www.payloadspace.comIgnition: www.ignition-news.comTectonic: www.tectonicdefense.com 

So here's the thing.Two years ago, when we were preparing for our visa interview + appointment, we did DIY. The process is doable, albeit frustrating at times when your total understanding of the process is toddler-level, and many times in the first year, I doubled-down on the DIY route.But in the past two years, we've seen drastic + rapid changes in the process that can catch you off guard if you are navigating the process alone.Enter Joao Madeira Pinto, our immigration attorney. You know - the guy we wish we had known in 2023? Because now that we know all that he does to help people navigate the visa process, we'd likely have said, please help us!In this week's episode, we give you Part 2 with Joao, where he highlights what he can offer someone who is interesting in moving to Portugal. Top prize goes to obtaining your NIF, opening a bank account within a week + even finding an apartment and securing that elusive lease requirement!To talk directly with Joao and get customized advice based on your plans + needs, Joao offers a FREE consultation call + discount to our listeners here. FYI - he's the best.Tune in and make the decision that works best for you.Cheers, y'all!Meredith + Mark[Joao Madeira Pinto, Certified Immigration Attorney]Website: www.madpintolaw.com To hear more, visit portugaljunkies.substack.com

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

Rustler Core Team Member Sonny Scroggin joins Elixir Wizards Sundi Myint and Charles Suggs. Rustler serves as a bridge to write Native Implemented Functions (NIFs) in Rust that can be called from Elixir code. This combo leverages Rust's performance and memory safety while maintaining Elixir's fault tolerance and concurrency model, creating a powerful solution for CPU-intensive operations within Elixir applications. Sonny provides guidance on when developers should consider using NIFs versus other approaches like ports or external services and highlights the considerations needed when stepping outside Elixir's standard execution model into native code. Looking toward the future, Sonny discusses exciting developments for Rustler, including an improved asynchronous NIF interface, API modernization efforts, and better tooling. While Rust offers tremendous performance benefits for specific use cases, Sonny emphasizes that Elixir's dynamic nature and the BEAM's capabilities for distributed systems remain unmatched for many applications. Rustler simply provides another powerful tool that expands what developers can accomplish within the Elixir ecosystem. Key topics discussed in this episode: Rust as a "high-level low-level language" with memory safety NIFs (Native Implemented Functions) in the BEAM virtual machine Rustler's role simplifying Rust-Elixir integration with macros CPU-intensive operations as primary NIF use cases Beam scheduler interaction considerations with native code Dirty schedulers for longer-running NIFs in OTP 20+ Memory safety advantages of Rust for NIFs Development workflow using Mix tasks for Rustler Common pitfalls when first working with Rust Error handling improvements possible with Rustler NIFs Differences between ports, NIFs, and external services Asynchronous programming approaches in Rust versus Elixir Tokyo runtime integration for asynchronous operations Static NIFs for mobile device compatibility Upcoming CLI tooling to simplify Rustler development Rustler's API modernization efforts for better ergonomics Thread pool sharing across multiple NIFs Wasm integration possibilities for the BEAM Compile-time safety versus dynamic runtime capabilities Performance considerations when implementing NIFs Compiler-assisted memory management in Rust Automatic encoding/decoding between Rust and Elixir types The importance of proper error handling Real-world application in high-traffic authentication servers Community resources for learning Rustler Links mentioned: https://github.com/rusterlium/rustler https://github.com/rust-lang/rust https://www.angelfire.lycos.com/ https://www.webdesignmuseum.org/flash-websites https://www.php.net/ https://xmpp.org/ https://jabberd2.org/ Geocities: https://cybercultural.com/p/geocities-1995/ (fun fact: when you search Geocities on Google, the results page is in Comic Sans font.) https://bleacherreport.com/ https://hexdocs.pm/jose/readme.html https://github.com/rust-lang/rust-bindgen Erlang Ports: https://www.erlang.org/doc/system/cport.html Erlang ETFs (External Term Format): https://www.erlang.org/doc/apps/erts/erlextdist.html Elixir gRPC https://github.com/elixir-grpc/grpc gRPC (“Remote Proceduce Call”): https://grpc.io/ dirtycpu.ex https://github.com/E-xyza/zigler/blob/main/lib/zig/nif/dirty_cpu.ex ets https://www.erlang.org/doc/apps/stdlib/ets.html Mnesia https://www.erlang.org/doc/apps/mnesia/mnesia.html VPPs (Virtual Power Plants): https://www.energy.gov/lpo/virtual-power-plants https://nixos.org/ WASM WebAssembly with Elixir: https://github.com/RoyalIcing/Orb Rust Tokio https://tokio.rs/ Getting Started: https://hexdocs.pm/rustler/0.17.0/Mix.Tasks.Rustler.New.html https://rustup.rs/ Special Guest: Sonny Scroggin.

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

In the Season 14 premiere, hosts Dan Ivovich and Sundi Myint chat with Isaac Yonemoto, creator of the Zigler library, to explore how Zigler brings Zig's performance and safety to Elixir through Native Implemented Functions (NIFs). Isaac walks through the core design of Zigler and how it auto-generates the Elixir-to-Zig bridge, enforces type safety, and exposes multiple execution modes (normal, dirty, threaded). The conversation covers real-world applications, from SIMD-powered token selection for LLM hardware acceleration to OTP-style fault tolerance in low-level code. Isaac shares his own journey: stepping back from professional software work to launch a biotech startup focused on reducing drug manufacturing costs while continuing to maintain Zigler and even leveraging Elixir for bioinformatics pipelines. Topics discussed in this episode: What is the Zigler library and what does it do? What does it mean to run a "dirty NIF"? Async mode is temporarily removed from Zig (therefore, yielding NIFs is temporarily deprecated in Zigler) Zigler's three execution modes (normal, dirty, and threaded) and how you switch modes with a single config change Isaac's journey from professional software work to launching a biotech startup How Isaac leverages Elixir in bioinformatics pipelines at his startup LLM hardware acceleration using Zigler NIFs and SIMD-powered token picking Fault-tolerant load balancing of NIF workloads via OTP principles Transparent handling and recovery from hardware failures through monitoring Potential future memory-safety features in Zig and their implications The Elixir-based borrow-checker prototype: purpose and design Unit-checking for scientific computations to enforce correctness New OS support in Zigler 0.14: macOS, Windows, and FreeBSD Inline Zig code authoring directly within Elixir modules Isaac's commitment to maintain Zigler through its 1.0 release (...and beyond?) Links mentioned: https://github.com/E-xyza/zigler https://github.com/ziglang/zig https://vidalalabs.com/ Zig Programming Language: https://ziglang.org/ https://obsidian.md/ https://hexdocs.pm/elixir/macros.html https://erlang.org/documentation/doc-4.7.3/doc/extensions/macros.html A Deep Dive Into the Elixir AST: https://dorgan.ar/posts/2021/04/theelixirast/ https://www.erlang.org/doc/system/nif.html https://nodejs.org/en Llama Open-Source LLM: https://www.llama.com/ Mixtral Open-Source LLM: https://mistral.ai/news/mixtral-of-experts https://Fly.io SIMD: https://en.wikipedia.org/wiki/Singleinstruction,multiple_data https://opentrons.com/ CI/CD: https://en.wikipedia.org/wiki/CI/CD https://hexdocs.pm/zigler/Zig.html http://www.x.com/DNAutics https://bsky.app/profile/dnautics.bsky.social

El abogado Sergio Marco ha sido elegido gerente, y como representantes de los diferentes comités, Teresa Vicente, profesora de Filosofía del derecho e impulsora de la ILP, representará a la Comisión de Representantes; Mario Cervera, alcalde de Los Alcázares, representará a la Comisión de Seguimiento, y el profesor de Ecología Miguel Ángel Esteve al Comité Científico.La profesora Teresa Vicente, impulsora de la Ley de personalidad jurídica del Mar Menor, califica este día como de "alfabetización" ecológica de la ciudadanía.Entre los integrantes de los diferentes comités se han dado cita representantes de sectores diversos y que hoy han compartido una posición común, la de "hacer lo que sea necesario" para proteger al Mar Menor.Así lo manifestaban representantes tanto de la agricultura como de defensa del patrimonio de corte ambientalista como son Vicente Carrión, presidente de COAG en la Comarca de Cartagena, y Ramón Pagán, portavoz de la Plataforma social Pacto por el Mar Menor.A partir de hoy, y según exige la Ley de Personalidad Jurídica del Mar Menor, ya se pueden iniciar los trámites para que el pequeño mar pueda obtener su NIF y, por lo tanto, operar con personalidad jurídica ante los tribunales y ante las administraciones.

This is our weekly compilation of science news.00:00 - New Nuclear Fusion Record at NIF! Can laser fusion break even?5:28 - The USA is crumbling at the bottom and sinking10:05 - Gravity might be a force after all15:11 - Black Holes might turn into White Holes, and make up dark matter, physicists say

Em vários países africanos, há sinais de que quando os governos conseguem cobrar impostos, também tendem a melhorar a qualidade da democracia. O economista angolano Francisco Paulo, acaba de terminar o doutoramento no Instituto Universitário de Lisboa com uma tese sobre “Tributação em África e Reformas Fiscais em Angola”, explica-nos que, quando os cidadãos começam a pagar impostos e percebem que estão a financiar os serviços públicos, ganham mais consciência cívica e exigem mais dos seus governantes. RFI: O que é que o motivou a estudar o tema dos impostos e por que escolheu Angola como caso de estudo?Francisco Paulo: O que me levou a estudar os impostos em África… sabe que o continente africano, na verdade, se analisarmos os dados macroeconómicos, é um dos continentes com menor colecta de impostos em comparação com os restantes. Em média, a percentagem dos impostos no PIB em África anda à volta dos 14%, enquanto noutros continentes ronda os 30%, 20%. África cobra menos impostos. E, se compararmos com os níveis de democracia, os países africanos também são, em geral, os que têm os níveis mais baixos de democracia.Por que é que África cobra menos impostos? Existem várias razões. A literatura aponta também alguns aspectos, como o facto de a democracia, em alguns países africanos, ser considerada imposta pelo Ocidente, no sentido de que grande parte da ajuda pública ao desenvolvimento é condicionada pelo respeito pelos direitos humanos e pela implementação da democracia. Quisemos analisar até que ponto a ajuda ao desenvolvimento contribui efectivamente para a democracia em África, e que impacto factores como os impostos podem ter no seu reforço, tendo em conta a teoria do contrato social.Nota-se que, quando a população começa a pagar impostos, desenvolve uma maior consciência cívica, especialmente nos países africanos, porque compreende que os serviços públicos prestados pelo governo não são gratuitos, e que participam nas despesas. Quando isso acontece, há níveis mais elevados de democracia e uma maior responsabilização por parte dos governos.O estudo mostra que há uma relação em forma de "U invertido" entre democracia e carga fiscal. Pode explicar-nos de forma simples o que isto quer dizer?Essa relação em forma de U invertido significa que, numa fase inicial, o aumento da carga fiscal ou seja, a carga fiscal que incide sobre a população e sobre as empresas, e não sobre a exploração de recursos naturais, contribui para o aumento dos índices de democracia. No entanto, esse aumento só ocorre até um certo limiar. No nosso estudo, esse limiar situa-se entre os 26% e os 27% de receitas fiscais em proporção do PIB.Se esse limiar for ultrapassado, um aumento na carga fiscal pode provocar uma diminuição nos índices de democracia. Quando os impostos se tornam demasiado elevados, as pessoas deixam de querer pagá-los. E os governos, por vezes, podem adoptar atitudes autoritárias para forçar o pagamento. Por isso, essa relação é em U invertido: o aumento da carga fiscal promove a democracia até certo ponto, depois disso, pode ter o efeito contrário.É isso que está a acontecer em Angola?Bom, em Angola, podemos notar que uma das melhores coisas que aconteceu nos últimos anos foi a diminuição das receitas fiscais petrolíferas. Com essa redução, o governo foi obrigado a começar a cobrar impostos ao sector não petrolífero.Esses impostos; como o IRT (Imposto sobre o Rendimento do Trabalho) e o IVA, afectam directamente a população, que sente que paga impostos, mas não vê retorno em termos de serviços públicos.A população não tem retorno?Não há retorno, e a população está cada vez mais consciente disso. Por exemplo, recentemente houve um caso de desvio de dinheiro na AGT relacionado com o IVA, e a população ficou completamente revoltada. Estávamos a falar com algumas pessoas que diziam: “Bom, quando havia dinheiro do petróleo, não se sentia tanto, porque o petróleo é uma economia de enclave, não havia esse impacto directo. Agora, quando roubam o dinheiro do IVA, estão a roubar o dinheiro dos mais pobres”.Isso mostra que a cobrança de impostos aumenta a consciência cívica. O imposto não é apenas um instrumento de arrecadação pública, mas também de participação cívica. E é a melhor forma de garantir uma democracia mais vibrante. A democracia precisa de receitas para funcionar, porque as instituições precisam de dinheiro, e esse dinheiro vem, em primeiro lugar, dos impostos.No seu trabalho encontra um resultado curioso: quando a economia não petrolífera cresce, a arrecadação de impostos fora do petróleo não aumenta. Como se explica isso?No caso específico de Angola, isso foi uma verdadeira surpresa para nós. O PIB não petrolífero é a base para a incidência dos impostos não petrolíferos. De acordo com a teoria económica, o aumento do PIB deveria levar ao aumento das receitas fiscais. Mas, em Angola, isso não aconteceu durante o período que analisámos (2008-2021).Durante esse período, as receitas fiscais não petrolíferas não acompanharam o crescimento do PIB não petrolífero. Isso é um paradoxo.E como se explica isso?Uma das razões prende-se com o facto de o governo ter concedido muitas isenções fiscais. Muitas empresas foram criadas e beneficiaram dessas isenções. Por exemplo, a Unitel, a maior empresa de telecomunicações de Angola, teve isenção de imposto industrial quando foi criada, e continua a ser uma das mais lucrativas do país. Até hoje, não sabemos se essa isenção já terminou, porque não há dados oficiais disponíveis.Essas isenções fiscais foram atribuídas de forma discricionária. Só em 2022 é que o governo aprovou o Código das Isenções Fiscais. Antes disso, qualquer ministério podia concedê-las. Foi então criada uma agência para este efeito, mas a Administração Geral Tributária não tem acompanhado,  ou, pelo menos, não há registos públicos das isenções concedidas.Essas isenções explicam a relação negativa entre o PIB não petrolífero e as receitas fiscais não petrolíferas. Infelizmente, a reforma tributária implementada pelo governo não abordou essa questão nem a redução da carga fiscal. E tudo foi feito na ânsia de atrair investimento privado, mas de forma pouco estruturada. Não há dados sobre o número de isenções concedidas. Procurámos essa informação junto da AGT, mas não conseguimos obtê-la. Enquanto o governo não se organizar neste sentido, essa relação negativa poderá persistir.A economia informal é um grande desafio em África e, claro, também em Angola. Que soluções existem, na sua opinião, para integrar mais trabalhadores e empresas no sistema formal de impostos?A economia informal em África é, em grande parte, consequência da má governação. A maioria das pessoas ou pequenos empresários não está na informalidade por vontade própria, estão por falta de opção.Dou-lhe um exemplo: em Angola, há muitos cidadãos que não têm bilhete de identidade. Hoje, o número de identificação fiscal (NIF) está ligado ao número do Bilhete de Identidade. Logo, quem não tem BI, não tem NIF e, por isso, não é reconhecido como contribuinte. Como é que essa pessoa vai formalizar o seu negócio?Isto revela falhas graves nas políticas públicas, quer no registo das pessoas, quer no registo da propriedade. Muitas propriedades não estão legalmente registadas: há pessoas que têm terrenos ou edifícios, mas não têm documentos legais que os comprovem. Essa falha obriga muitas pessoas à informalidade.E a informalidade não é sustentável. Se muitos desses trabalhadores e empresas fossem formalizados, isso representaria um aumento significativo nas receitas fiscais, quer em impostos sobre empresas e rendimento, quer em impostos indirectos.Francisco Paulo, uma última questão. Com base na sua investigação, que recomendações deixaria aos governos africanos para aumentarem a receita fiscal sem pôr em risco a estabilidade social e política?Analisámos a curva de Laffer, que mede a relação entre a taxa de impostos e a receita fiscal em termos monetários. E notámos que, no que toca ao imposto sobre empresas e aos impostos indirectos, muitos países africanos já atingiram o seu limite. Não há margem para aumentar ainda mais as taxas porque quem já paga impostos são sempre os mesmos, os formalizados. Isso gera uma sobrecarga injusta.A melhor forma de expandir a base tributária é formalizar a economia informal. Para isso, é essencial investir no registo civil das pessoas, no registo da propriedade e na educação. Isso incentivaria as pessoas a formalizarem os seus negócios.Os governos africanos devem canalizar os seus gastos públicos para a melhoria efectiva das condições de vida da população. Quando as pessoas percebem que os seus impostos estão a ser bem utilizados; quando vêem melhorias nas infra-estruturas, na saúde, na educação, estão mais dispostas a pagar impostos. E isso, por sua vez, pode contribuir para melhores índices de democracia em África.

I den nyeste episoden av i loopen får du en dyptgående samtale med Zaineb Al-Samarai, Idrettspresident, NIF, Anita Leirvik North, Byråd for kultur og næring (H), og Jannicke Aas, daglig leder i Vålerenga Samfunn.Med Danat Tekie som programleder utforsker vi hvordan idretten kan bygge broer i samfunnet, samt de reelle utfordringene rundt økonomiske barrierer for deltakelse. Gjestene deler verdifulle og ufiltrerte perspektiver og presenterer konkrete løsninger for å sikre at idretten forblir tilgjengelig for alle.En spennende samtale for alle som er opptatt av idrett og samfunnsutvikling!Husk å abonnere! Hosted on Acast. See acast.com/privacy for more information.

News includes the release of Elixir 1.18.2 with various enhancements and bug fixes, a new experimental SQL sigil for Ecto that brings automatic parameterized queries, a recent GOTO 2025 talk featuring Saša Jurić on code reviews. We talked with Jonatan Kłosko about his work on PythonX, a new library for executing Python code inside Elixir, the Fine library for working with C++ NIFs, and much more! Show Notes online - http://podcast.thinkingelixir.com/244 (http://podcast.thinkingelixir.com/244) Elixir Community News https://gigalixir.com/thinking (https://gigalixir.com/thinking?utm_source=thinkingelixir&utm_medium=shownotes) – Visit Gigalixir.com to sign up and get 20% off your first year. Or use the promo code "Thinking" during signup. https://github.com/elixir-lang/elixir/releases/tag/v1.18.2 (https://github.com/elixir-lang/elixir/releases/tag/v1.18.2?utm_source=thinkingelixir&utm_medium=shownotes) – Elixir 1.18.2 was released with enhancements to Code.Fragment and Regex, plus bug fixes for CLI, ExUnit, IEx.Autocomplete, and mix deps.update. https://github.com/elixir-lang/elixir/releases/tag/v1.18.1 (https://github.com/elixir-lang/elixir/releases/tag/v1.18.1?utm_source=thinkingelixir&utm_medium=shownotes) – Elixir 1.18.1 included bug fixes for Kernel, ExUnit.Case, mix compile.elixir, mix escript.build, and Mix.Shell, especially related to error handling and Windows compatibility. https://www.erlang.org/news/174 (https://www.erlang.org/news/174?utm_source=thinkingelixir&utm_medium=shownotes) – Erlang OTP 28 RC-1 is out with a new source Software Bill of Materials (SBOM) on the Github Releases page. https://github.com/elixir-dbvisor/sql (https://github.com/elixir-dbvisor/sql?utm_source=thinkingelixir&utm_medium=shownotes) – A new experimental SQL sigil for Ecto brings an extensible SQL parser to Elixir with automatic parameterized queries. https://groups.google.com/g/elixir-ecto/c/8MOkRFAdLZc (https://groups.google.com/g/elixir-ecto/c/8MOkRFAdLZc?utm_source=thinkingelixir&utm_medium=shownotes) – The experimental SQL sigil for Ecto is being discussed on the Elixir-Ecto mailing list. https://www.youtube.com/watch?v=AYUNI2Pm6_w (https://www.youtube.com/watch?v=AYUNI2Pm6_w?utm_source=thinkingelixir&utm_medium=shownotes) – New talk from GOTO 2025 with Saša Jurić and Adrienne Braganza Tacke on "Small PRs, Big Impact - The Art of Code Reviews." https://alchemyconf.com/ (https://alchemyconf.com/?utm_source=thinkingelixir&utm_medium=shownotes) – AlchemyConf is coming up March 31 - April 3 in Braga, Portugal. https://www.gigcityelixir.com/ (https://www.gigcityelixir.com/?utm_source=thinkingelixir&utm_medium=shownotes) – GigCity Elixir and NervesConf are happening in Chattanooga, TN, USA with NervesConf on May 8 and the main event on May 9-10. https://www.elixirconf.eu/ (https://www.elixirconf.eu/?utm_source=thinkingelixir&utm_medium=shownotes) – ElixirConf EU will be held May 15-16, 2025 in Kraków & Virtual. https://goatmire.com/#tickets (https://goatmire.com/#tickets?utm_source=thinkingelixir&utm_medium=shownotes) – Goatmire tickets are on sale now for the event happening September 10-12, 2025 in Varberg, Sweden. Do you have some Elixir news to share? Tell us at @ThinkingElixir (https://twitter.com/ThinkingElixir) or email at show@thinkingelixir.com (mailto:show@thinkingelixir.com) Discussion Resources https://dashbit.co/blog/dashbit-plans-2025 (https://dashbit.co/blog/dashbit-plans-2025?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/thewca/wca-live (https://github.com/thewca/wca-live?utm_source=thinkingelixir&utm_medium=shownotes) – Speed cubing software https://dashbit.co/blog/running-python-in-elixir-its-fine (https://dashbit.co/blog/running-python-in-elixir-its-fine?utm_source=thinkingelixir&utm_medium=shownotes) https://hexdocs.pm/pythonx/Pythonx.html (https://hexdocs.pm/pythonx/Pythonx.html?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/livebook-dev/pythonx (https://github.com/livebook-dev/pythonx?utm_source=thinkingelixir&utm_medium=shownotes) https://bsky.app/profile/josevalim.bsky.social/post/3liyrfvlth22c (https://bsky.app/profile/josevalim.bsky.social/post/3liyrfvlth22c?utm_source=thinkingelixir&utm_medium=shownotes) – Jose said “We said we will focus on interoperability for 2025 and we are ready to share the first results.” https://github.com/elixir-nx/fine (https://github.com/elixir-nx/fine?utm_source=thinkingelixir&utm_medium=shownotes) – “Fine” is a new package related to the elixir-nx organization. It's a C++ library enabling more ergonomic NIFs, tailored to Elixir. https://peps.python.org/pep-0703/ (https://peps.python.org/pep-0703/?utm_source=thinkingelixir&utm_medium=shownotes) – Discussion about removing the Python GIL Find us online - Message the show - Bluesky (https://bsky.app/profile/thinkingelixir.com) - Message the show - X (https://x.com/ThinkingElixir) - Message the show on Fediverse - @ThinkingElixir@genserver.social (https://genserver.social/ThinkingElixir) - Email the show - show@thinkingelixir.com (mailto:show@thinkingelixir.com) - Mark Ericksen on X - @brainlid (https://x.com/brainlid) - Mark Ericksen on Bluesky - @brainlid.bsky.social (https://bsky.app/profile/brainlid.bsky.social) - Mark Ericksen on Fediverse - @brainlid@genserver.social (https://genserver.social/brainlid) - David Bernheisel on Bluesky - @david.bernheisel.com (https://bsky.app/profile/david.bernheisel.com) - David Bernheisel on Fediverse - @dbern@genserver.social (https://genserver.social/dbern)

Dive into this episode of The Brand Called You with Prof. Anil Sahasrabudhe, a luminary in India's educational landscape. From his inspiring personal journey to his visionary role in leveraging technology for equitable and innovative learning, this discussion covers groundbreaking insights on India's National Education Policy, fostering innovation, and integrating the rich Indian Knowledge System into modern education.00:39- About Prof Anil Sahasrabudhe Professor Sahasrabudhe is the chairman of NETF, NBA, EC, NAAC and NIF. He is a distinguished figure in India's educational landscape.

Olá Bom Dia ALEGRIA! Munson here with the Good Morning Portugal! show, livestream & podcast... We start the show with the all-new 'Bom Dia Daily' - 20 minutes of news, weather, language, culture & wellbeing in Portugal, by way of an introduction today to...Lighthouse Consulting's Raquel and our mate Nuno Mendes, who'll be talking about the 'Power of the NIF', and how and when to use it, as well as providing their monthly business world update.Comments in the chat, pics & vids to WhatsApp (00 351) 913 590 303Get more at www.goodmorningportugal.com / Support the show and join the Portugal Club at www.gmpvip.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-good-morning-portugal-podcast-with-carl-munson--2903992/support.

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

In this special 200th episode of NucleCast, Jill Hruby, the Administrator of NNSA and Undersecretary of the Department of Energy for Nuclear Security, discusses the achievements and challenges faced by NNSA during her tenure, including the modernization of nuclear weapons, strengthening international partnerships, and the importance of infrastructure projects. Jill shares insights on the Strategic Posture Commission's recommendations, the plans for pit production, and the significance of the National Ignition Facility (NIF). She emphasizes the need for a renewed focus on nuclear IQ and offers advice for future leadership in the nuclear enterprise.Administrator Jill Hruby was Senate confirmed as the Under Secretary for Nuclear Security of the U.S. Department of Energy (DOE) and Administrator of the National Nuclear Security Administration in 2021.Administrator Hruby leads NNSA in achieving our Nation's nuclear security missions to sustain and fully understand our nuclear weapons stockpile; provide new technologies and procedures to lower cost and reduce the time to deliver all mission requirements; staying ahead of our adversaries; and developing advanced capabilities to enhance nuclear security, arms control, and Navy reactors.Prior to her nomination as Administrator, Ms. Hruby served as Director of Sandia National Laboratories from 2015-17 and has an extensive background in science and engineering spanning more than 40 years.Chapters00:00 Introduction to NNSA and Jill Hruby01:31 Reflecting on Achievements and Challenges04:34 Infrastructure Projects and Challenges10:18 Strategic Posture Commission Insights12:30 Pit Production Plans and Timelines16:31 NIF and Its Significance19:41 Increased Activity Across NNSA22:17 Advice for Future Leadership26:08 Wishes for the Nuclear Enterprise29:53 Parting Message and Future OutlookSocials:Follow on Twitter at @NucleCastFollow on LinkedIn: https://linkedin.com/company/nuclecastpodcastSubscribe RSS Feed: https://rss.com/podcasts/nuclecast-podcast/Rate: https://podcasts.apple.com/us/podcast/nuclecast/id1644921278Email comments and topic/guest suggestions to NucleCast@anwadeter.org

I això vol dir poder tenir un NIF propi per facilitar i agilitzar la gestió de situacions puntuals, o d'imponderables que sorgeixen i que han de poder resoldre's al moment, fins a la cerca de noves fonts d'ingressos a través de patrocinis o d'altres recursos. La nova comissió de Festa Major, presidida per Xavier Salmeron, creu que es pot aconseguir i que no seria cap novetat, tenint en compte que les comissions de Vilafranca i Vilanova tenen NIF propi. A la vegada, hi ha la consciència que la proposta podria esdevenir un precedent aplicable a d'altres comissions. Tot plegat amb l'objectiu que la comissió de Festa Major es pugui dedicar veritablement als aspectes troncals de la Festa, com son el seu desenvolupament, la seva difusió i coneixement, i la proposta d'iniciatives que la puguin fer encara més participativa i propera per als qui en són nouvinguts. Ens ho han explicat Xavier Salmeron, acompanyat de Maria Junyent, Gabri González i Irene Martinez. L'entrada La nova comissió de Festa Major es proposa com un dels objectius prioritaris poder gestionar-se com una associació per impulsar noves iniciatives ha aparegut primer a Radio Maricel.

News includes Saša Jurić updating his project for "The Soul of Erlang and Elixir" talk with the latest technologies, the release of Phoenix LiveView RC 8 with exciting new features, ErrorTracker v0.5.0's enhancements for Ash applications, and the introduction of the NX MLX backend for Apple Silicon, offering efficient machine learning on Mac hardware. Plus, a new VS Code plugin called "Refactorex" brings robust refactoring capabilities to Elixir. We also interview Gonzalo Rodriguez about Tower, a vendor-agnostic error tracking and reporting tool in Elixir, discussing its creation, functionality, and how it simplifies error management across various services. And more! Show Notes online - http://podcast.thinkingelixir.com/232 (http://podcast.thinkingelixir.com/232) Elixir Community News https://x.com/sasajuric/status/1863889108449337415 (https://x.com/sasajuric/status/1863889108449337415?utm_source=thinkingelixir&utm_medium=shownotes) – Saša Jurić updated the project used in his "The Soul of Erlang and Elixir" talk, rewriting it with the latest versions of Erlang, Elixir, & Phoenix. https://github.com/sasa1977/souloferlangandelixir (https://github.com/sasa1977/soul_of_erlang_and_elixir?utm_source=thinkingelixir&utm_medium=shownotes) – The updated GitHub project for "The Soul of Erlang and Elixir" talk, now using the latest technologies. https://www.youtube.com/watch?v=JvBT4XBdoUE (https://www.youtube.com/watch?v=JvBT4XBdoUE?utm_source=thinkingelixir&utm_medium=shownotes) – Saša Jurić's 2019 talk "The Soul of Erlang and Elixir" is available on YouTube. https://github.com/phoenixframework/phoenixliveview/blob/main/CHANGELOG.md#100-rc8-2024-12-02 (https://github.com/phoenixframework/phoenix_live_view/blob/main/CHANGELOG.md#100-rc8-2024-12-02?utm_source=thinkingelixir&utm_medium=shownotes) – Phoenix LiveView RC 8 is out, with new features like extended HEEx syntax and more. From RC7, there is support for targeting inner and closest query selectors in JS commands. https://x.com/crbelaus/status/1861450830181720333 (https://x.com/crbelaus/status/1861450830181720333?utm_source=thinkingelixir&utm_medium=shownotes) – ErrorTracker v0.5.0 release includes support for Ash applications, better mobile experience, and more. https://bsky.app/profile/samrat.me/post/3lbzwr7gxmk2q (https://bsky.app/profile/samrat.me/post/3lbzwr7gxmk2q?utm_source=thinkingelixir&utm_medium=shownotes) – The NX MLX backend for Apple Silicon is announced, offering efficient machine learning on Apple hardware. https://github.com/elixir-nx/emlx (https://github.com/elixir-nx/emlx?utm_source=thinkingelixir&utm_medium=shownotes) – GitHub repository for NX MLX, Elixir support for the Apple MLX machine learning framework on Apple Silicon. MLX is designed by Apple for efficient machine learning on MacOS hardware. https://github.com/cocoa-xu/nif_call (https://github.com/cocoa-xu/nif_call?utm_source=thinkingelixir&utm_medium=shownotes) – Cocoa's nif_call package allows calling Elixir functions from inside a NIF. https://bsky.app/profile/zachdaniel.dev/post/3lc2leowiek26 (https://bsky.app/profile/zachdaniel.dev/post/3lc2leowiek26?utm_source=thinkingelixir&utm_medium=shownotes) – Zach Daniel's ElixirConf EU talk on the Ash framework is available on YouTube. https://www.youtube.com/watch?v=vjnPjrCF4rs (https://www.youtube.com/watch?v=vjnPjrCF4rs?utm_source=thinkingelixir&utm_medium=shownotes) – Ash: The Story of a Function by Zach Daniel explains why Ash exists and the problems it solves. https://github.com/gp-pereira/refactorex (https://github.com/gp-pereira/refactorex?utm_source=thinkingelixir&utm_medium=shownotes) – New VS Code plugin "Refactorex" by Gabriel Pereira for refactoring Elixir code with several built-in refactorings. https://adventofcode.com/2024/ (https://adventofcode.com/2024/?utm_source=thinkingelixir&utm_medium=shownotes) – Advent of Code is active, with people participating using their favorite programming languages. https://notes.club (https://notes.club?utm_source=thinkingelixir&utm_medium=shownotes) – A platform that hosts a frontend of Livebooks on GitHub, organized by author, likes, and tags, useful for exploring how people are solving Advent of Code problems in Elixir. https://github.com/ljgago/kino_aoc (https://github.com/ljgago/kino_aoc?utm_source=thinkingelixir&utm_medium=shownotes) – A GitHub repository for a Livebook Smart Cell which aids in solving Advent of Code directly from Livebook. https://github.com/nettinho/smaoc (https://github.com/nettinho/smaoc?utm_source=thinkingelixir&utm_medium=shownotes) – Another Livebook Smart Cell repository on GitHub for Advent of Code that facilitates problem interaction within Livebook. Do you have some Elixir news to share? Tell us at @ThinkingElixir (https://twitter.com/ThinkingElixir) or email at show@thinkingelixir.com (mailto:show@thinkingelixir.com) Discussion Resources https://www.mimiquate.com/blog/tower-universal-and-agnostic-elixir-exception-tracking (https://www.mimiquate.com/blog/tower-universal-and-agnostic-elixir-exception-tracking?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mimiquate/tower (https://github.com/mimiquate/tower?utm_source=thinkingelixir&utm_medium=shownotes) – The root Tower project https://github.com/mimiquate/tower_email (https://github.com/mimiquate/tower_email?utm_source=thinkingelixir&utm_medium=shownotes) – Email sending when error encountered (uses Swoosh) https://github.com/mimiquate/towererrortracker (https://github.com/mimiquate/tower_error_tracker?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mimiquate/tower_sentry (https://github.com/mimiquate/tower_sentry?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mimiquate/tower_slack (https://github.com/mimiquate/tower_slack?utm_source=thinkingelixir&utm_medium=shownotes) Pull requests for the mentioned Bandit updates https://github.com/mtrudel/bandit/pull/411 (https://github.com/mtrudel/bandit/pull/411?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mtrudel/bandit/pull/417 (https://github.com/mtrudel/bandit/pull/417?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mtrudel/bandit/pull/420 (https://github.com/mtrudel/bandit/pull/420?utm_source=thinkingelixir&utm_medium=shownotes) Guest Information https://x.com/grzuy (https://x.com/grzuy?utm_source=thinkingelixir&utm_medium=shownotes) – on Twitter/X https://github.com/grzuy/ (https://github.com/grzuy/?utm_source=thinkingelixir&utm_medium=shownotes) – on Github https://bsky.app/profile/grzuy.bsky.social (https://bsky.app/profile/grzuy.bsky.social?utm_source=thinkingelixir&utm_medium=shownotes) – on Bluesky Find us online Message the show - Bluesky (https://bsky.app/profile/thinkingelixir.com) Message the show - X (https://x.com/ThinkingElixir) Message the show on Fediverse - @ThinkingElixir@genserver.social (https://genserver.social/ThinkingElixir) Email the show - show@thinkingelixir.com (mailto:show@thinkingelixir.com) Mark Ericksen on X - @brainlid (https://x.com/brainlid) Mark Ericksen on Bluesky - @brainlid.bsky.social (https://bsky.app/profile/brainlid.bsky.social) Mark Ericksen on Fediverse - @brainlid@genserver.social (https://genserver.social/brainlid) David Bernheisel on Bluesky - @david.bernheisel.com (https://bsky.app/profile/david.bernheisel.com) David Bernheisel on Fediverse - @dbern@genserver.social (https://genserver.social/dbern)

In this episode, Josh and Kalie from ExpatsEverywhere dive into a Q&A format, addressing various questions from their patrons about living in Portugal. They cover topics such as understanding taxi lights, navigating phone plans, the timing for obtaining a NIF and bank account, hiring housekeepers, visa income requirements, and the differences between D7 and D8 visas. They also discuss language courses for citizenship, finding accommodation, renewing temporary residency while applying for citizenship, and compare dental care in Portugal to the US. The episode concludes with insights on EU citizenship and the golden visa investment maintenance.MALO Clinic: https://www.maloclinics.com/en/general-appointment-form?utm_source=expats_everywhere?utm_medium=social_partnership?utm_campaign=BF_NOV ★ Support this podcast on Patreon ★

May I introduce you to my husband.nnIf you are introducing a person by their first name, without including their title, you add an ‘a' before the name:nnExample: Le presento a Ray Blakney -> May I introduce you to Ray Blakney.nnIf you are introducing a person with their title you add either an ‘a la' if they are female or ‘al', spelled ‘A-L' if they are male. That is just contraction of ‘a el'.nnExample: Le presento a la doctora Sánchez -> May I introduce you to Dr. Sánchez.nnNow, repeat all the following phrases out loud, but add the word ‘le presento' at the beginning of each one.nnExample: A mi hijo -> Le presento a mi hijo.nnFind more practice exercises in this blog post after listening to the episode.nnDon't forget to subscribe here, rate 5 stars, and leave a review!"}" data-sheets-userformat= "{"2":14465,"3":{"1":0,"3":1},"10":1,"14":{"1":3,"3":1},"15":"Arial","16":10}"> Let's practice introducing others. To introduce others we will use the phrase ‘le presento' which means ‘may I introduce you to'. This is followed by my ‘mi' if you are introducing a family member, since you are implying a relationship to you. Example: Le presento a mi esposo -> May I introduce you to my husband. If you are introducing a person by their first name, without including their title, you add an ‘a' before the name: Example: Le presento a Ray Blakney -> May I introduce you to Ray Blakney. If you are introducing a person with their title you add either an ‘a la' if they are female or ‘al', spelled ‘A-L' if they are male. That is just contraction of ‘a el'. Example: Le presento a la doctora Sánchez -> May I introduce you to Dr. Sánchez. Now, repeat all the following phrases out loud, but add the word ‘le presento' at the beginning of each one. Example: A mi hijo -> Le presento a mi hijo. Find more practice exercises in this blog post after listening to the episode. Don't forget to subscribe here, rate 5 stars, and leave a review!

Jasmine Mund, mechanical engineer, gives today's Fusion News update - summarizing the major recent headlines in fusion energy. Links to all of the stories mentioned are included below. 1. Groundbreaking research at NSIRC and Lancaster University set to transform fusion reactor development https://www.cambridgenetwork.co.uk/news/groundbreaking-research-nsirc-and-lancaster-university-set-transform-fusion-reactor 2. Multinational fusion energy project marks completion of its most complex magnet system https://phys.org/news/2024-07-multinational-fusion-energy-complex-magnet.html 3. ITER fusion reactor hit by massive decade-long delay and €5bn price hike https://physicsworld.com/a/iter-fusion-reactor-hit-by-massive-decade-long-delay-and-e5bn-price-hike/ Bonus: What next: Further implosion space exploration on the path to NIF extended yield capability https://pubs.aip.org/aip/pop/article/31/6/062712/3299549/What-next-Further-implosion-space-exploration-on?searchresult=1 Nuclear fusion challenges: Low pressure, high temperature, and the electromagnetic field https://www.power-technology.com/sponsored/nuclear-fusion-challenges-low-pressure-high-temperature-and-the-electromagnetic-field/ FIA Launches 2024 Supply Chain Report https://www.fusionindustryassociation.org/fia-launches-2024-supply-chain-report/ Fusion Industry Association and The Fusion Cluster Lay Out Strategic Priorities Ahead of UK Election https://www.fusionindustryassociation.org/fusion-industry-association-and-the-fusion-cluster-lay-out-strategic-priorities-ahead-of-uk-election/

If you're looking to move to Portugal + need to know more about how to get here on the D7 retirement (or passive income) visa, look no further. As a follow up to our last episode overview, Mark + I go in depth on the actual application requirements one-by-one and give you some big picture perspective about WHY they are asking you for this stuff + how to best position yourself for an approval on your visa application. Key Resources: ⁠Portugal Junkies Resources⁠ (1:1 Calls, Free Templates, Referrals for NIF, Bank Account + Lease Reviews) ⁠VFS Global Website⁠ ⁠AmericansandFriends PT Facebook Group⁠ ⁠Idealista Website FREE D7 Personal Statement Template

If you're looking to move to Portugal + need to know more about how to get here on the D7 retirement (or passive income) visa, look no further. As a follow up to our last episode overview, Mark + I go in depth on the actual application requirements one-by-one and give you some big picture perspective about WHY they are asking you for this stuff + how to best position yourself for an approval on your visa application. Key Resources: ⁠⁠Portugal Junkies Resources⁠⁠ (1:1 Calls, Free Templates, Referrals for NIF, Bank Account + Lease Reviews) ⁠⁠VFS Global Website⁠⁠ D7 Documentation Checklist D7 Application ⁠⁠AmericansandFriends PT Facebook Group⁠⁠ ⁠⁠Idealista Website⁠ ⁠FREE D7 Personal Statement Template

If you're looking to move to Portugal + need to know more about how to get here on the D7 retirement (or passive income) visa, look no further. Mark + I give a high level overview of the process, timelines and how to prepare to put your best self forward in your application. Stay tuned for the next two episodes where we go in depth on the actual application requirements one-by-one and give you some big picture perspective about WHY they are asking you for this stuff! Key Resources: Portugal Junkies Resources (1:1 Calls, Free Templates, Referrals for NIF, Bank Account + Lease Reviews) VFS Global Website AmericansandFriends PT Facebook Group Idealista Website

In neurocritical care, the initial evaluation is often fast paced, and assessment and management go hand in hand. History, clinical examination, and workup should be obtained while considering therapeutic implications and the need for lifesaving interventions. In this episode, Aaron Berkowitz, MD, PhD FAAN, speaks with Sarah Wahlster, MD, an author of the article “The Neurocritical Care Examination and Workup,” in the Continuum June 2024 Neurocritical Care issue. Dr. Berkowitz is a Continuum® Audio interviewer and professor of neurology at the University of California San Francisco, Department of Neurology and a neurohospitalist, general neurologist, and a clinician educator at the San Francisco VA Medical Center and San Francisco General Hospital in San Francisco, California. Dr. Wahlster is an associate professor of neurology in the departments of neurology, neurological surgery, and anesthesiology and pain medicine at Harborview Medical Center, University of Washington in Seattle, Washington. Additional Resources Read the article: The Neurocritical Care Examination and Workup Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz Guest: @SWahlster Full Episode Transcript Sarah Wahlster, MD   Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, a companion podcast to the journal. Continuum Audio features conversations with the guest editors and authors of Continuum, who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article by clicking on the link in the Show Notes. Subscribers also have access to exclusive audio content not featured on the podcast. As an ad-free journal entirely supported by subscriptions, if you're not already a subscriber, we encourage you to become one. For more information on subscribing, please visit the link in the Show Notes. AAN members: stay tuned after the episode to hear how you can get CME for listening.  Dr Berkowitz: This is Dr Aaron Berkowitz, and today I'm interviewing Dr Sarah Wahlster about her article on examination and workup of the neurocritical care patient, which is part of the June 2024 Continuum issue on neurocritical care. Welcome to the podcast, Dr Wahlster. Can you please introduce yourself to the audience? Dr Wahlster: Thank you very much, Aaron. I'm Sarah Wahlster. I'm a neurologist and neurontensivist at Harborview Medical Center at the University of Washington. Dr Berkowitz: Well, Sarah and I know each other for many, many years. Sarah was my senior resident at Mass General and Brigham and Women's Hospital. Actually, Sarah was at my interview dinner for that program, and I remember meeting her and thinking, “If such brilliant, kind, talented people are in this program, I should try to see if I can find my way here so I can learn from them.” So, I learned a lot from Sarah as a resident, I learned a lot from this article, and excited for all of us to learn from Sarah, today, talking about this important topic. So, to start off, let's take a common scenario that we see often. We're called to the emergency room because a patient is found down, unresponsive, and neurology is called to see the patient. So, what's running through your mind? And then, walk us through your approach as you're getting to the bedside and as you're at the bedside. Dr Wahlster: Yeah, absolutely. This was a fun topic to write about because I think this initial kind of mystery of a patient and the initial approach is something that is one of the puzzles in neurology. And I think, especially if you're thinking about an emergency, the tricky part is that the evaluation and management go hand in hand. The thinking I've adapted as a neurointensivist is really thinking about “column A” (what is likely?) and “column B” (what are must-not-miss things?). It's actually something I learned from Steve Greenberg, who was a mutual mentor of us - but he always talked me through that. There's always things at the back of your head that you just want to rule out. I do think you evaluate the patient having in mind, “What are time-sensitive, critical interventions that this patient might need?” And so, I think that is usually my approach. Those things are usually anything with elevated intracranial pressure: Is the patient at risk of herniating imminently and would need a neurosurgical intervention, such as an EVD or decompression? Is there a neurovascular emergency, such as an acute ischemic stroke, a large-vessel occlusion, a subarachnoid hemorrhage that needs emergent intervention? And then other things you think about are seizures, convulsive/nonconvulsive status, CNS infection, spinal cord compression. But I think, just thinking about these pathologies somewhere and then really approaching the patient by just, very quickly, trying to gather as much possible information through a combination of exam and history. Dr Berkowitz: Great. So, you're thinking about all these not-to-miss diagnoses that would be life-threatening for the patient and you're getting to the bedside. So, how do you approach the exam? Often, this is a different scenario than usual, where the patient's not going to be able to give us a history or maybe necessarily even participate in the exam, and yet, as you said, the stakes are high to determine if there are neurologic conditions playing into this patient's status. So, how do you approach a patient at the bedside? Dr Wahlster: So, I think first step in an ICU setting (especially if the patient has a breathing tube) is you think about any confounders (especially sedation or metabolic confounders) - you want to remove as soon as possible, if able. I think as you do the exam, you try to kind of incorporate snippets of the history and really try to see - you know, localize the problem. And also kind of see, you know, what is the time course of the deterioration, what is the time course of the presentation. And that is something I actually learned from you. I know you've always had this framework of “what is it, where is it?” But I think in terms of just a clinical exam, I would look at localizing signs. I think, in the absence of being able to do the full head-to-toe neuro exam and interact with the patient, you really try to look at the brainstem findings. I always look at the eyes right away and look at, I think, just things like, you know, the gaze (how is it aligned? is there deviation? is there a skew? what do the pupils look like? [pupillary reactivity]). I think that's usually often a first step - that I just look at the patient's eyes. I think other objective findings, such as brainstem reflexes and motor responses, are also helpful. And then you just look whether there's any kind of focality in terms of - you know, is there any difference in size? But I think those are kind of the imminent things I look at quickly. Dr Berkowitz: Fantastic. Most of the time, this evaluation is happening kind of en route to the CT scanner or maybe a CT has already happened. So, let's say you're seeing a patient who's found down, the CT has either happened or you asked for it to happen somewhat quickly after you've done your exam, and let's say it's not particularly revealing early on. What are the sort things on your exam that would then push you to think about an MRI, a lumbar puncture, an EEG? You and I both spend time in large community hospitals, right, where “found down” is one of the most common chief concerns. In many cases, there isn't something to see on the CT or something obvious in the initial labs, and the question always comes up, “Who gets an MRI? Who gets an LP? Who gets an EEG?” - and I'm not sure I have a great framework for this. Obviously, you see focality on your exam, you know you need to look further. But, any factors in the history or exam that, even with a normal CT, raise your suspicion that you need to go further? Dr Wahlster: It's always a challenge, especially at a community hospital, because some of these patients come in at 1 AM where the EEG is not imminently available. But I think - let's say the CT scan is absolutely normal and doesn't give me a cause, but as an acute concerning deterioration, I think both EEG and LP would cross my mind. MRI I kind of see a little bit as a second-day test. I think there's very rare situation where an acute MRI would inform my imminent management. It's very informative, right, because you can see very small-vessel strokes. We had this patient that actually had this really bad vasculitis and we were able to see the small strokes everywhere on the MRI the day later, or sometimes helps you visualize acute brainstem pathology. But I think, even that - if you rule out a large-vessel occlusion on your CTA, there's brainstem pathology that is not imminently visible on the CT - it's nothing you need to go after. So, I do think the CT is a critical part of that initial eval, and whereas I always admire the neurological subspecialties, such as movements, where you just – like, your exam is everything. I think, to determine these acute time-sensitive interventions, the CT is key. And also, seeing a normal CT makes me a little less worried. You always look at these “four H” (they're big hypodensity, hyperdensity, any shift; is there hydrocephalus or herniation). I think if I don't have an explanation, my mind would imminently jump to seizure or CNS infection, or sometimes both. And I think then I would really kind of - to guide those decisions and whether I want to call in the EEG tech at 2 AM - I would, you know, again, look at the history and exam, see if there's any gaze deviation, tongue biting, incontinence - anything leading up towards seizure. I think, though, even if I didn't have any of those, those would strengthen my suspicion. If I really, absolutely don't have an explanation and the patient off sedation is just absolutely altered, I would still advocate for an EEG and maybe, in the meantime, do a small treatment trial. And I think with CNS infection - obviously, there are patients that are high risk for it - I would try to go back and get history about prodromes and, you know, look at things like the white count, fevers, and all of that. But again, I think if there's such a profound alteration in neurologic exam, there's nothing in the CT, and there's no other explanation, I would tend to do these things up front because, again, you don't want to miss them. Dr Berkowitz: Yeah, perfect. So many pearls in there, but one I just want to highlight because I'm not sure I've heard the mnemonic - can you tell us the four Hs again of sort of neurologic emergencies on CT? Dr Wahlster: Yeah. So, it's funny; for ages - I'm actually not sure where that's coming from, and I learned it from one of my fellows, one of our neurocritical care fellows - he's a fantastic teacher and he would teach our EM and anesthesia residents about it and his approach to CT. But yeah, the four H - he was always kind of like, “Look at the CT. Do you see any acute hypodensities, any hyperdensities?” And hypodensities would be involving infarct or edema; hyperdensities would be, most likely, hemorrhage (sometimes calcification or other things). Then, “Do you see hydrocephalus?” (because that needs an intervention). And, “Look at the midline structures and the ventricles.” And then, “Do you see any signs of herniation?” And he would go through the different types of herniation. But I thought that's a very good framework for looking at the “noncon” and just identifying critical pathology that needs some intervention. Dr Berkowitz: Yeah – so, hypodensity, hyperdensity, herniation, hydrocephalus. That's a good one – the four Hs; fantastic. Okay. So, a point that comes up a few times in your article - which I thought was very helpful to walk through and I'd love to pick your brain about a little bit – is, which patients need to be intubated for a neurologic indication? So, often we do consultations in medical, surgical ICUs; patients are intubated for medical respiratory reasons, but sometimes patients are intubated for neurologic reasons. So, can you walk us through your thinking on how to decide who needs to be intubated for the concern of depressed level of consciousness? Dr. Wahlster: It's an excellent question, and I think I would bet there's a lot of variation in practice and difference in opinion. There was actually the 2020 ESICM guidelines kind of commented on it, and those are great guidelines in terms of just intubation, mechanical ventilation of patients, and just acknowledging how there is a lack of really strong evidence. I would say the typical mantra (“GCS 8, intubate”) has been proposed in the trauma literature. And at some point, I actually dug into this to look behind the evidence, and there's actually not as much evidence as it's been put forth in guidelines and that kind of surprised me - that was just recently. I was like, “Actually, let me look this up.” I would say I didn't find a ton of strong evidence for it. I would say, as neurologist – you know, I'm amazed because GCS, I think is a - in some ways, a good tool to track things because it's so widely used across the board. But I would say, as neurologists, we all know that it sometimes doesn't account for some sort of nuances; you know, if a patient is aphasic, if a patient has an eyelid-opening apraxia - it can always be a little confounded. I'm amazed that GCS is still so widely used, to be frank. But I would say there is some literature - some school of thought - that maybe just blindly going by that mantra could be harmful or could not be ideal. I would say – I mean, I look at the two kind of functional things: oxygenation and ventilation. I think, in a neuro patient, you always think about airway protection or the decreased level of consciousness being a major issue (What is truly airway protection? Probably a mix of things). Then there's the issue of respiratory centers and respiratory drive - I think those are two issues you think about. But ultimately, if it leads to insufficient oxygenation - hypoxia early on is bad and that's been shown in several neurologic acute brain injuries. I think you also want to think about ventilation, especially if the mental status is poor to the point that the PCO2 elevates, that could also augment an ICP or exacerbate an ICP crisis. Or sometimes, I think there's just dysregulation of ventilation and there's hyperventilation to the point that the PCO2 is so low that I worry about cerebral vasoconstriction. So, I worry about these markers. I think, the oxygenation, I usually just kind of initially track on the sats. Sometimes, if the patient is profoundly altered, I do look at an arterial blood gas. And then there are things like breathing sounds (stridor, stertor [the work of breathing]). And I think something that also makes me have a lower threshold to intubate is if I'm worried and I want to scan, and I'm worried that the patient can't tolerate it - I want an imminent scan to just see why the patient is altered, or seizing, or presenting a certain way. Dr Berkowitz: All great pearls for how to think through this. Yeah - it's hard to think of hard and fast rules, and you can get to eight on the GCS in many different ways, as you said, some of which may not involve the respiratory mechanics at all. So, that's a helpful way of thinking about it that involves both the mental state, kind of the tracheal apparatus and how it's being managed by the neurologic system, and also the oxygen and carbon dioxide (sort of, respiratory parameters) – so, linking all those together; that's very helpful. And, related question – so, that's sort of for that patient with central nervous system pathology, who we're thinking about whether they need to be intubated for a primary neurologic indication. What about from the acute neuromuscular perspective (so, patients with Guillain-Barré syndrome or myasthenic crisis); how do you think about when to intubate those patients? Dr Wahlster: Yeah, absolutely - I think that's a really important one. And I think especially in a patient that is rapidly progressing, you always kind of think about that, and you want them in a supervised setting, either the ER or the ICU. I mean, there's some scores - I think there's the EGRIS score; there's some kind of models that predict it. I would say, the factors within that model, and based on my experience, often the pace of progression of reflex motor syndrome. I often see things like, kind of, changes in voice. You know, myasthenia, you look at things like head extension, flexion - those are the kind of factors. I would say there's this “20/30/40 rule” about various measures of, like, NIF and vital capacities, which is great. I would say in practice, I sometimes see that sometimes the participation in how the NIF is obtained is a little bit funky, so I wouldn't always blindly go by these numbers but sometimes it's helpful to track them. If you get a reliable kind of sixty and suddenly it drops to twenty, that makes me very concerned. But I would say, in general, it's really a little bit the work of breathing - looking at how the patient looks like. There's also (at some point) ABG abnormalities, but we always say, once those happen, you're kind of later in the game, so you should really - I think anyone that is in respiratory distress, you should think about it and have a low threshold to do it, and, at a minimum, monitor very closely. Dr Berkowitz: Yeah, we have those numbers, but so often, our patients who are weak, from a neuromuscular perspective, often have facial and other bulbar weakness and can't make a seal on the device that is used to check these numbers, and it can look very concerning when the patient may not, or can be a little bit difficult to interpret. So, I appreciate you giving us sort of the protocol and then the pearls of the caveats of how to interpret them and going sort of back to basics. So, just looking at the patient at the bedside and how hard they are working to breathe, or how difficult it is for them to clear their secretions from bulbar weakness. Moving on to another topic, you have a really wonderful section in your article on detecting clinical deterioration in patients in the neuro ICU. Many patients in the neuro ICU - for example, due to head trauma or large ischemic stroke or intracerebral hemorrhage, subarachnoid hemorrhage, or status epilepticus - they can't communicate with us to tell us something is getting worse, and they can't (in many cases) participate in the examination. They may be intubated, as you said, sedated or maybe even not sedated, and there's not necessarily much to follow on the exam to begin with if the GCS is very low. So, I'd love to hear your thoughts and your pearls, as someone who rounds in the neuro-ICU almost every day. What are you looking for at the bedside to try to detect sort of covert deterioration, if you will, in patients who already have major neurologic deficits, major neurologic injury or disease that we're aware of? I'm trying to see if there is some type of difference at the bedside that would lead you to be concerned for some underlying change and go back to the scanner or repeat EEG, LP, et cetera. Dr Wahlster: Yeah. I think that's an excellent question because that's a lot of what we do in the neuro ICU, right? And when you read your Clans, your residency, like, “Ah, QNR neuro checks, [IG1]  ” right? We often do that in many patients. But I think in the right patient, it can really be life or death a matter, and it is the exam that really then drives a whole cascade of changes in management and detects the need for lifesaving procedure. I would say it depends very much on the process and what you anticipate, right? If you have, for example, someone with a large ischemic stroke, large MCA stroke, especially, right, then there's sometimes conversations about doing a surgical procedure before they herniate. But let's say, kind of watch them and are worried that they will, you do worry about uncal herniation, and you pay attention to the pupil, because often, if the inferior division is infarcted, you know, you can see that kind of temporal tickling the uncus already. And so, I think those are patients that I torture with those NPi checks and checking the pupil very vigilantly. I would say, if it's a cerebellar stroke, for example, right, then you think about, you know, hydrocephalus. And often patients with cerebellar stroke - you know, the beauty of it is that if you detect it early, those patients can do so well, but they can die, and will die if they develop hydrocephalus start swelling. But I think, often something I always like to teach trainees is looking at the eye movements in upgaze and downgaze because, often, as the aqueduct, the third ventricle gets compressed and there's pressure on the colliculi – you kind of see vertical gaze get worse. But I would say I think it's always good to know what the process is and then what deterioration would look like. For example, in subarachnoid hemorrhage, where you talk about vasospasm - it's funny - I think a really good, experienced nurse is actually the best tool in this, but they will sometimes come to you and say, “I see this flavor,” and it's actually a constellation of symptoms, especially in the anterior ACA (ACom) aneurysms. You sometimes see patients suddenly, like, making funky jokes or saying really weird things. And then you see that in combination with, sometimes, a sodium drop, a little bit of subfebrile temperature; blood pressure shoot up sometimes, and that is a way the brain is sometimes regulating. But it's often a constellation of things, and I think it depends a little on the process that you're worried about. Dr Berkowitz: Yeah, that's very helpful. You just gave us some pearls for detecting deterioration related to vasospasm and subarachnoid hemorrhage; some pearls for detecting malignant edema in an MCA stroke or fourth ventricular compression in a large cerebellar stroke. Patients I find often very challenging to get a sense of what's going on and often get scanned over and over and back on EEG, not necessarily find something: patients with large intracerebral hemorrhage (particularly, in my experience, if the thalamus is involved) just can fluctuate a lot, and it's not clear to me actually what the fluctuation is. But you're looking for whether they're developing hydrocephalus from third ventricular compression with a thalamic hemorrhage (probably shouldn't be seizing from the thalamus, but if it's a large hemorrhage and cortical networks are disrupted and it's beyond sort of the subcortical gray matter, or has the hemorrhage expanded or ruptured it into the ventricular system?) And yet, you scan these patients over and over, sometimes, and just see it's the same thalamic hemorrhage and there's some, probably, just fluctuation level of arousal from the thalamic lesion. How do you, as someone who sees a lot of these patients, decide which patients with intracerebral hemorrhage - what are you looking for as far as deterioration? How do you decide who to keep scanning when you're seeing the same fluctuations? I find it so challenging - I'm curious to hear your perspective. Dr Wahlster: Yeah, no - that is a very tricky one. I mean, unfortunately, in patients with deeper hemorrhages or deeper lesions - you know, thalamic or then affecting brainstem - I think those are the ones that ultimately don't have good, consistent airway protection and do end up needing a trach, just because there's so much fluctuation. But I agree - it's so tricky, and I don't think I can give a perfect answer. I would say, a little bit I lean on the imaging. And for example - let's say there's a thalamic hemorrhage. We recently actually had a patient - I was on service last week - we had a thalamic hemorrhage with a fair amount of edema on it that was also kind of pressing on the aqueduct and didn't have a lot of IVH, right? But it was, like, from the outside pushing on it and where we ended up getting more scans. And I have to say, that patient actually just did fine and actually got the drain out and didn't need a shunt or anything, and actually never drained. We put an EVD and actually drained very little. So, I think we're still bad at gauging those. But I think, in general, my index of suspicion or threshold to scan would be lower if there was something, like, you know, a lot of IVH associated, if, you know, just kind of push on the aqueduct. It's very hard to say, I think. Sometimes, as you get to know your patients, you can get a little bit of a flavor of what is within normal fluctuation. I think it's probably true for every patient, right? - that there's always some fluctuation within the realm of like, “that's what he does,” and then there's something more profound. Yeah, sorry - I wish I could give a better answer, but I would say it's very tricky and requires experience and, ideally, you really taking the time to examine the patient yourself (ideally, several times). Sometimes, we see the patient - we get really worried. Or the typical thing we see the ICU is that the neurosurgeons walk around at 5 AM and say, like, “She's altered, she's different, she's changed.” And then the nurse will tell you at 8 AM, like, “No, they woke up and they ate their breakfast.” So, I think really working with your nurse and examining the patient yourself and just getting a flavor for what the realm of fluctuation is. Dr Berkowitz: Yeah - that's helpful to hear how challenging it is, even for a neurocritical care expert. I'm often taking care of these patients when they come out of the ICU and I'm thinking, “Am I scanning these patients too much?” Because I just don't sort of see the initial stage, and then, you know, you realize, “If I'm concerned and this is not fitting, then I should get a CT scan,” and sometimes you can't sort it out of the bedside. So, far from apologizing for your answer, it's reassuring, right, that sometimes you really can't tell at the bedside, as much as we value our exam. And the stakes are quite high if this patient's developed intraventricular hemorrhage or hydrocephalus, and these would change the management. Sometimes you have these patients the first few days in the ICU (for us, when they come out of the ICU) are getting scanned more often than you would like to. But then you get a sense of, “Oh, yeah - these times of day, they're hard to arouse,” or, “They're hard to arouse, but they are arousable this way,” and then, “When they are aroused, this is what they can do, and that's kind of what we saw yesterday.” And yet, as you said, if anyone on the team (the resident, the nurse, the student, our neurosurgery colleague) says, “I don't think this is how they were yesterday,” then, very low threshold to just go back and get a CT and make sure we're not missing something. Dr. Wahlster: Exactly. Yeah. I would say the other thing is also certain time intervals, right? If I'm seeing a patient that may be in vasospasm kind of around the days seven to ten, for the first fourteen day, I would be a little bit more nervous. Or with swelling - acute ischemic stroke says that could peak swelling, when knowing which [IG2]  , I would just be more anxious or have a lower threshold to scan. Yeah. Dr Berkowitz: Yeah - very helpful. Well, thank you so much for joining me today on Continuum Audio. Dr Wahlster: Thank you very much, Aaron. Dr Berkowitz: Again, today we've been interviewing Dr Sarah Wahlster, whose article, “Examination and Workup of the Neurocritical Care Patient” appears in the most recent issue of Continuum, on neurocritical care. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining us today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practice. And right now, during our Spring Special, all subscriptions are 15% off. Go to Continpub.com/Spring2024 or use the link in the episode notes to learn more and take advantage of this great discount. This offer ends June 30, 2024. AAN members: go to the link in the episode notes and complete the evaluation to get CME. Thank you for listening to Continuum Audio.

A unique coming of age story, Aggressive Optimism explores the complex landscape of mental health, the importance of solidarity, and the power of perseverance.'Nif is a talented singer trapped in a small hometown. Though she thrives in her choir, she longs for a life in Hollywood. After a breakthrough solo performance, her talents are recognized by a popular media personality and her hopes for her big break soar. Until a devastating accident derails her dreams and confronts her with new and unexpected challenges. With the help of her family and dear friends, Nif must reassemble the pieces of her life and discover a wellspring of inner strength. In the process, her aggressive optimism becomes a source of inspiration, not only for herself but for those around her.'Bio - Jenna EdwardsGrowing up in the middle of Minnesota's cornfields, Jenna had some big dreams. She wanted to make people laugh on TV, inspire change, and travel the world. Life wasn't easy, though. Born to teenage parents who split when she was three, Jenna faced poverty and abuse until her mom took a stand, and they escaped.In her early twenties, Jenna set off for Los Angeles, to make her dreams come true. She even landed a role on the legendary "Buffy the Vampire Slayer" show. Imagine inheriting Buffy's powers! But then, a terrible accident shook her world. She struggled with debilitating Post Traumatic Stress Disorder (PTSD) but learned that asking for help is a sign of strength, just like Buffy asking her friends for help.Websitewww.jennaedwards.comSocial Media InformationIG @jennaedwardsofficialResources MentionedBig Magic - Elizabeth GilbertShow Sponsor – National Association for Primary Education (NAPE) www.nape.org.ukSupport the show at www.educationonfire.com/supportHave you seen our live shows on YouTube? www.EducationOnFire.com/youtube

Наш ведущий Тимур спустя полгода жизни в Португалии наконец-то смог собрать себя в кучу и записать сумбурный выпуск про свою жизнь здесь. Если у вас есть предложения, вопросы или идея по поводу контента про жизнь в Португалии, то пишите нам на почту zavtracast@gmail.com. Подписывайтесь и ставьте лайк, а также не забудьте нажать на колокольчик на нашем ютубе – https://youtube.com/zavtracast    Если вы хотите нас поддержать из России, то подписывайтесь на нас на Boosty – https://boosty.to/zavtracast Если вы находитесь за границей, то можно подписаться на нас еще и на сервисе Patreon – https://patreon.com/zavtracast  Подписывайтесь на каналы ведущих в Телеграме: – Фотодушнила – https://t.me/dushovato – Сказки Дядюшки Зомбака – https://t.me/zombaktales В целом про выбор страны и какие у вас есть альтернативы, если вы хотите в Европу и не хотите зависеть от контракта (Португалия, Испания, Италия, Турция). Про цены в Португалии и как здесь существенно экономить без напряга. Как выбрать регион и город для проживания, а также какие могут быть особенности. Чем грозит жить на “отшибе Европы”. Сколько стоит обогреть квартиру электричеством и зачем нужны дегидраторы. Как получить визу Digital Nomad – читать гайды или обращаться к профессионалам (например, Татьяна – https://t.me/Tanchela_s) Почему нельзя забывать про всякие мелочи типа контрактов, NIF, NISS, Utente […] Запись Завтракаст – Portugal Special впервые появилась Zavtracast.

  Positron Range Correction PET Hunor Kertesz Image X institute @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Hunor Kertesz about how he has implemented  Positron Range Correction PET with commercial PET scanners! This can make huge improvements in PET especially in cardiac and Gallium PET. TAGS PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Positron Range Correction PETHunor Kertesz Image X institute @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Hunor Kertesz about how he has implemented  Positron Range Correction PET with commercial PET scanners! This can make huge improvements in PET especially in cardiac and Gallium PET. TAGS PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

As private and government interest in nuclear fusion technology grows, an array of startups have arisen to take on the challenge, each with their own unique approach. Among them: LaserFusionX. Today on Faster, Please!—The Podcast, I talk with CEO Stephen Obenschain about the viability of fusion energy, and what sets his approach apart.Obenschain is the president of LaserFusionX. He was formerly head of the Plasma Physics Division branch at the U.S. Naval Research Laboratory.In This Episode* Viability of commercial fusion (0:58)* The LaserFusionX approach (7:54)* Funding the project (10:28)* The vision (12:52)Below is a lightly edited transcript of our conversationViability of commercial fusion (0:58)Pethokoukis: Steve, welcome to the podcast.Obenschain: Okay, I'm glad to talk with you. I understand you're very interested in high-tech future power sources, not so high tech right now are windmills…Well, I guess they're trying to make those more high tech, as well. I recall that when the Energy Department, the National Ignition Laboratory [NIF], they had the—I guess that's over about maybe 15 months ago—and they said they had achieved a net gain nuclear fusion, using lasers, and the energy secretary made an announcement and it was a big deal because we had never done that before by any means. But I remember very specifically people were saying, “Listen, it's a great achievement that we've done this, but using lasers is not a path to creating a commercial nuclear reactor.” I remember that seemed to be on the news all the time. But yet you are running a company that wants to use lasers to create a commercial fusion reactor. One, did I get that right, and what are you doing to get lasers to be able to do that?I don't know why people would come to that conclusion. I think we are competitive with the other approaches, which is magnetic fusion, where you use magnetic fields to confine a plasma and get to fusion temperatures. The federal government has supported laser fusion since about 1972, starting with the AEC [Atomic Energy Commission]. Originally it was an energy program, but it has migrated to being in support stockpiled stewardship because, with laser fusion, you can reach physics parameters similar to what occur in thermonuclear weapons.Yeah. So that facility is about nuclear weapons testing research, not creating a reactor—a fusion reactor.Yeah. All that being said, it does advance the physics of laser fusion energy, and what the National Ignition Facility did is got so-called ignition, where the fuel started a self-sustaining reaction where it was heating itself and increasing the amount of fusion energy. However, the gain was about three, and one of the reasons for that is they use so-called indirect drive, where the laser comes in, heats a small gold can, and the X-rays from that then that drive the pellet implosion, which means you lose about a factor of five in the efficiency. So it's limited gain you get that way.Your way is different. It sort of cuts out the middleman.Okay. The better way to go—which, we're not the only ones to do this—is direct drive, where the laser uniformly illuminates the target at the time that Livermore got started with indirect drive, we didn't have the technologies to uniformly illuminate a pellet. First at NRL [Naval Research Laboratories], and then later at University of Rochester in Japan, they developed techniques to uniformly illuminate the pellets. The second thing we're doing is using the argon fluoride laser. The argon fluoride laser has been used in lithography for many years because it's deep UV.The unique thing we have been trying to do—this was when I was supervising the program at the Naval Research Laboratory—was to take it up to high energy. We started years ago with a similar Krypton fluoride laser, built the largest operating target shooter with that technology, demonstrated the high repetition rate operation that you need for energy and NIF will shoot a few times a day—you need five to 10 shots per second to do a power plant—demonstrated that on a krypton fluoride laser, and, more recently, we switched to the focus to argon fluoride, which is deeper UV and more efficient than the Krypton  fluoride. And that basically—at NRL when I was supervising it—reached the energy record for that technology. But we've got a long ways to go to get it to the high energy needed for a power plant.Now, what the immediate goal of my company is to get the funds and to build a beam line of argon fluoride that would have the energy and performance needed for a power plant. One of the advantages to laser fusion: you want have a situation where I'm building more than one of something, so for an implosion facility, you have many beam lines, so you build one and then you have the advantage of building more, and a learning curve as you go toward a power plant. We developed a phase program where first we build the beamline, then we build a NIF-like implosion facility only operating with the argon fluoride, demonstrate the high gain—which is a hundred plus for a power plant—and then, after doing that, do the physics in parallel, develop the other technology you need, like low-cost targets. (They can't be expensive. The NIF targets are probably tens of thousands. We can't spend that.) We're going 10 shots per second. All the technologies required for a pilot power plant build a pilot power plant, which, in my view could be maybe 400 megawatts electricity. However, its main function would be to develop the procedures, test the components, and so forth for the follow-on, mass-produced power plants. So one, when you build a pilot power plant, you want to operate it for a few years to get the kinks out before going to mass production. The vision is to go from the beginning of that to the end in about 16 years.So the challenges are you have to generate enough heat, and you have to be able to do this over, and over, and over again.Right. That's right. It has to be high reliability. For an implosion facility, a hundred-thousand-shot reliability is okay. For a power plant, it's got to be in the billion-shot class.And at this point, the reason you think this is doable is what?I think we have confidence in the pellet designs. I have a lot, and I have colleagues that have a lot of experience with building large excimer systems: KrF [Krypton Fluoride Excimer Laser], ArF [Argon Fluoride Excimer Laser]…Those are lasers?Yes. And we have credible conceptual designs for the facility.There's a lot of companies right now, and startups, with different approaches. I would assume you think this is the most viable approach, or has some other advantages over some of the other things we're seeing with Commonwealth Fusion Systems, which gets mentioned a lot, which is using a different approach. So is the advantage you think it's easier to get to a reactor? What are the advantages of this path?The LaserFusionX approach (7:54)Well, for one, it's different. It's different challenges from the Commonwealth Fusion Systems. There is overlap, and there should be collaboration. For example, you have to, theirs is also deuterium-tritium. However, the physics challenges are different. I think we're farther along in laser fusion to be able—it's a simpler situation than you have. It's very complex interactions in tokamak, and you also have things… have you ever heard of a disruption? Basically it's where all of the magnetic energy all of a sudden goes to the wall, and if you have something like what Commonwealth Fusion Systems—they've got to be careful they don't get that. If they do, it would blow a hole in the wall. We don't have that problem with laser fusion. I think we're further along in understanding the physics. Actually, the National Ignition Facility is ahead of the highest fusion gains they've gotten in facilities. I think that they're somewhere just below one or so with the jet. They're up at one and a half. To what extent are the challenges of physics and science, and to what extent are the challenges engineering?Well, the physics has to guide the precision you have on the laser. And I won't say we're 100 percent done in the physics, but we're far enough along to say, okay. That's one reason where I envision building an implosion facility before the pilot power plant so we can test the codes and get all the kinks out of that. Nothing's easy. You have to get the cost of the targets down. The laser, okay, we've demonstrated, for example, at NRL—And NRL is…?Naval Research Laboratory.Naval Research Lab, right.A hundred-shot operation of the KrF laser. We use spark gap for that. We need to go to solid state pulse power, got up to 10 million shots. We need to get from there to a billion shots. And some of that is just simply improving the components. It's straightforward, but you've got to put time into it. I think you need really smart people doing this, that are creative—not too creative, but where you need to be creative, you are creative, and I think if, basically, if you can get the support, for example, to build (a beam line is somewhere around a hundred million dollars). To build the implosion facility and pilot power plant, you're getting into the billion shot, billion dollar class and you have to get those resources and be sure enough that, okay, if the investors put this money in, they're going to get a return on it.Funding the project (10:28)I think people who are investing in this sector, I would assume they may be more familiar with some of the other approaches, so what is the level of investor interest and what is the level of Department of Energy interest?Well, one of the challenges is that, historically, the Department of Energy has put money into two pots. One, laser fusion for stockpile stewardship, and magnetic fusion for energy. That's starting to change, but they don't have a lot of money involved yet, to put money into laser fusion or inertial fusion energy. And one of my challenges is not that the companies are aware of magnetic fusion, they don't understand the challenges of that, or laser fusion, or what's a good idea and a bad idea. And like Commonwealth Fusion systems I think has a good technical basis. If you go the next one down to Helion Energy, they're claiming they can burn helium three made from deuterium interactions, which violates textbook physics, so I'm very… I wonder about that.Would it surprise you, at the end of the day, that there are multiple paths to a commercial fusion reactor?Oh no. I think there are multiple paths to getting to where I get fusion burn, and maybe I make electricity. I think ultimately the real challenge for us is: Can we go reasonably fast? At 16 years, I'm considered somewhat slower than others. The ones that are saying five years I think are delusional. The ones that are saying 50 years, or say never, I don't think understand that yeah, we're pretty far along in this.How big, or rather, how small, theoretically, could one of these reactors be? I know there's been talk about using nuclear fusion as a way to provide power for these new data centers that gobble up so much power that they're using AI for. Would this be the kind of reactor that would power a city power, a big factory power, a data center, all of the above?I think you can get down, at least with our approach, to a couple hundred megawatts. However, my own vision is you're probably better off having power stations for some of the nuclear—with these, the big nuclear plants have multiple reactors at one place, and you'd get the advantage, for example, in our case, to just simply have one target factory and so forth. I don't think we're going to be able to compete. I don't know how small modular reactors go—a hundred megawatts or so, I would guess, and probably can't get down there, but one of my own goals is to get the size down as much as possible, but I think we're talking about hundreds of megawatts. The vision (12:52)What's the big vision? Why are you doing this?Why am I doing it?Yeah, what's the vision? What drives you and where do you think this goes over the next two decades?I may have the best route to get there. If I thought one of these other ones were going to get there, no problem… but all of us have challenges, and I think we can get there. I think from a standing start. As far as getting investment, I've just had pre-seed money, I don't have the big bucks yet. I've brought on people that are more experienced than me at extracting money from VCs and investors. (I was told you know a few billionaires.) Basically, for me, I need a few tens of millions to get started—like I'd say, about a hundred million to build the beamline. And then after that… actually I have a conference call on Friday with a representative of the investment bank industry that is very dubious about fusion.I mean, you can understand the skepticism, as a technology. What do they say? “It's the future of energy and always will be.”But the really good thing, I think, about the private investment is that the public investment has been too much focus on big machines which will give you physics, but have pretty much zero chance of being a direct path to fusion energy. You know, $25 billion and I make 500 megawatts thermal, occasionally, and we show that to a power plant executive, they're going to say, “You're kidding me.” We hope to get down cost for the power plants in the few-billion-dollar range.Faster, Please! is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit fasterplease.substack.com/subscribe

Please consider donating to our good friend Sue Lee Bun and help her fight Cancer. gofundme.com/teamsuebun https://venmo.com/u/Bun-TrailWelder The National Ignition Facility at Lorence Livermore Labs is where they cause the Big Bang. Jimmy and Tyler were lucky enough to be invited on a tour of the NIF. This is where they superheat small molecules and create fusion power. They learned so much about lasers and it made them feel like their lasers were very inadequate. Send us old license plates:SnailTrail4x4 / MORRFlate1065 National Dr, Suite 5, Sacramento, CA 95834 Want to win some Tires? Our friends at Yokohama are donating a set of tires for the 750 Apple Podcast reviews giveaway winner. Also, like before, we will give away swag packs every 50 until we get to the main giveaway. All reviews need to be left on Apple Podcast to be entered. Congratulations to TannerIsCooler for winning the 550 reviews swag pack. CALL US AND LEAVE US A VOICEMAIL!!!! We want to hear from you even more!!! You can call and say whatever you like! Ask a question, leave feedback, correct some information about welding, say how much you hate your Jeep, and wish you had a Toyota! We will air them all, live, on the podcast! +01-916-345-4744. If you have any negative feedback, you can call our negative feedback hotline, 408-800-5169. 4Wheel Underground has all the suspension parts you need to take your off-road rig from leaf springs to a performance suspension system. We just ordered our kits for Kermit and Samantha and are looking forward to getting them. The ordering process was quite simple and after answering the questionnaire to ensure we got the correct and best-fitting kits for our vehicles. If you want to level up your suspension game, check out 4Wheel Underground. Episode 477 is brought to you by all of our peeps over at patreon.com and irate4x4! Make sure to stop by and see all of the great perks you get for supporting SnailTrail4x4! Discount Codes, Monthly Give-Always, Gift Boxes, the SnailTrail4x4 Community, and the ST4x4 Treasure Hunt! Thank you to all of those who support us! We couldn't do it without you guys (and gals!)! Febuary's Giveaway is a set of 17" Coyote Inner Beadlocks. Inner Beadlocks are a fantastic way to make your wheels have the beadlock feature when you don't have beadlock wheels. It not only locks in the outer beadlock like everyone is used to but it also locks the inner bead as well. Jimmy runs a version of these on Bobcat and absolutely loves them. Massive thanks to MORRFlate for donating a full set of Coyote Inner Beadlocks for this months giveaway. If you're interested in winning this month's giveaway make sure you sign up on Irate4x4.com Snail Squad Membership. Congratulations to Sergio Rodriguez for winning January's Giveaway is with RollerCam. RollerCam makes quick and easy tie-down straps for everyday purposes. Their new patented design helps you sinch down the strap tightly and helps hold a tighter strength than traditional cam straps. Their new Rope Roller works with Paracord and allows you to tighten any situation quickly. If you need some tie-down straps make sure to sign up for the giveaway tier on Irate4x4.com Listener Discount Codes: SnailTrail4x4 -SnailTrail15 for 15% off SnailTrail4x4 MerchMORRFlate - snailtrail to get 10% off MORRFlate Multi Tire Inflation Deflation™ KitsIronman 4x4 - snailtrail20 to get 20% off all Ironman 4x4 branded equipment!Sidetracked Offroad - snailtrail4x4 (lowercase) to get 15% off lights and recovery gearSpartan Rope - snailtrail4x4 to get 10% off sitewideShock Surplus - SNAILTRAIL4x4 to get $25 off any order!Mob Armor - SNAILTRAIL4X4 for 15% offSummerShine Supply - ST4x4 for 10% off4WheelUnderground - snailtrail for 5% Midroll Music by ComaStudio

If hindsight is 20/20, then this podcast can help you forecast your future in a global lifestyle. Kristin shares 7 things she wishes she knew about living overseas before she moved abroad for the first time (back in 2002).    Check the show notes below for lots of great resources from this episode!    SPECIAL OFFERS:  Annual Feedback Survey (Win a Free Call with Kristin) Apply for moving overseas support Digital Nomads For Dummies book Get $10 off a NISS or NIF in Portugal with Bordr Portugal Trip Survey (Help Kristin plan a future group trip) Join Kristin's Newsletter   RELATED PODCASTS: Ep 212: 8 Ways to Overcome Reverse Culture Shock   RELATED VIDEOS: 7 Things to Know BEFORE You Move Abroad The Downsides of Living Abroad  What I Love About Living Abroad How I See the US After Living Abroad My Experience Living Japan as an Expat Living in the UK as an American (Culture Shock)   ADDITIONAL RESOURCES: tbd   Connect with Kristin and Support the Show: *   Become a Patron *   Buy a Coffee *   Follow on Instagram *   Join the Facebook Group *   Leave a 5-Star Review *   Subscribe on YouTube   See the show notes pages on BadassDigitalNomads.com or TravelingwithKristin.com/podcast  for time stamps, transcripts, and more resources from this episode.

What is nuclear fusion?Nuclear fusion produces energy by fusing atoms together. Atomic cores (nuclei) merge together to form a heavier—though unstable—nucleus, releasing mass to regain stability. This mass release corresponds to an energy release, given Einstein's equation E=mc2, which says in part that mass and energy can be converted into each other. The sun, along with all other stars, uses nuclear fusion to generate energy, which is released as heat and light. The 2022 Fusion Breakthrough In late 2022, scientists led by Dr. Annie Kritcher at the Lawrence Livermore National Laboratory (LLNL) briefly replicated the power of the sun. Replicating the sun's power requires replicating the extreme heat and density conditions within the sun's core. Atomic cores are positively charged, meaning they repel each other. To overcome this barrier, scientists need to apply massive amounts of heat and keep atomic cores extremely close together. For the first time, scientists produced more energy from fusion than the amount of energy it took to maintain these conditions. Fusion is a greenhouse-gas-free source of potentially unlimited electricity, powered by hydrogen we can take from water, and creating no long-lived radioactive waste. According to the International Atomic Energy Agency, fusion generates four times more energy per kilogram than the fission used for powering nuclear plants, and nearly 4 million times more energy than burning fossil fuels for energy. What's Next?Commercial nuclear fusion is still a long way off. While the physics aspect of fusion is “solved,” fusion remains a complicated engineering problem. The National Ignition Facility (NIF) at Lawrence Livermore National Laboratory has the most powerful laser in the world to blast heat at atoms, but it is the size of three football stadiums, very old, slow, inefficient, and clunky. There are still unanswered questions, such as how to affordably capture fusion energy, and how to keep a fusion reaction going for a long period of time. And although the laser shots at the NIF were weaker than its fusion output, the amount of energy drawn from the grid to create those lasers is 120 times more than the fusion output generated at LLNL. About Dr. Annie KritcherDr. Annie Kritcher is a nuclear engineer and physicist at the National Ignition Facility at Lawrence Livermore National Laboratory Weapons and Complex Integration's Design Physics Division. She led the recent nuclear fusion breakthrough at LLNL. In 2022, Kritcher was elected fellow of the American Physical Society. She earned her PhD at UC Berkeley. Further ReadingA shot for the ages: Fusion ignition breakthrough hailed as ‘one of the most impressive scientific feats of the 21st century' | Lawrence Livermore National LaboratoryUK Power Grid Could Have First Commercial Fusion Reactor By 2030sWorld's largest nuclear fusion reactor promises clean energy, but the challenges are huge - ABC NewsAnnie Kritcher leads revolutionary nuclear fusion experimentIAEA, What is nuclear fusion?NOVA Now Universe Revealed Podcast, Can We Recreate the Power of Stars Down on Earth? (YouTube or NOVA Podcast website) For a transcript, please visit https://climatebreak.org/the-clean-energy-potential-of-nuclear-fusion-with-annie-kritcher/

At this point in the game if you've been following this podcast within the past 2 years you know how high of a regard we hold Shaykh Hanif's pen! The South End raised lyricist has captured the ear of the streets since his release from prison a few years back and has hit the ground running–creating timeless music, along with his Feed The Family camp! The last time we spoke to 'Nif it was over a year ago on episode 135 and he's been growing his following and influence in a major way. Just after dropping his most recent album "Wilderness of North America", Shaykh Hanif visited Shade45's "Showoff Radio" w/ Statik Selektah & Termanology before making his way back home to our podcast for this conversation highlighting the body of work. Linking up with Westside Gunn, our guy OT The Real, and Benny The Butcher, it's safe to say "The Saudi Prince" is well on his way into the right rooms!Join Charlie MaSheen, Gina Rodriguez, & KASH this week as we talk to Hanif about his latest project, touch on the disaster going on in the Middle East from the perspective of a man of Islamic religion, breaking down the album "Wilderness of North America" and SO MUCH MORE!!! And in traditional fashion, Shaykh Hanif ended the conversation with a SENSATIONAL #RedCupsAndRap Freestyle which can be viewed on our YouTube Channel! TAP IN!!!BE SURE TO GO BUY/STREAM SHAYKH HANIF's ALBUM "Wilderness of North America" AVAILABLE ON ALL DSPs!!!CHECK OUT ALL OF OUR CONTENT:http://www.linktr.ee/CWTFBradio

When the Supreme Court overturned Roe v. Wade last year, it sent the issue of legalizing abortion back to the states. After the court's decision, Ohio enacted a near-total ban on abortion--which remained legal for a little over two months until a Hamilton County judge placed the law on hold due to a lawsuit from the ACLU and Planned Parenthood. Currently, abortion is legal in Ohio before 22 weeks of pregnancy. With Issue 1, abortion proponents hope to enshrine the right to abortion in the state's constitution.rnrnIf passed, Issue 1 would allow a patient to "make and carry out one's own reproductive decisions, including decisions about abortion, contraception, fertility treatment, miscarriage care, and continuing pregnancy." It would still allow the state to restrict abortion after fetal viability, except when "necessary to protect the pregnant patient's life or health. Opponents to Issue 1 argue the amendment would increase access to abortions, remove parental rights, allow gender affirming care for minors.

Innovator, storyteller, philanthropist, and impatient optimist, Mick Ebeling is a Muhammad Ali Humanitarian of the Year, Fortune “Top 50 World's Greatest Leaders” and a 2x TIME “Top 50 inventor”. He has sparked a movement of pragmatic, inspirational innovation as a career producer and filmmaker, and is now the founder and CEO of Not Impossible Labs. Mick has dedicated his life to tapping into the power of technology and story to help elevate our world. Join Mick as we discuss with him the road from film to foundation and the impact NIF aims to keep building for us all. 

En el episodio de hoy vamos a darle la bienvenida a una invitada muy querida: la profesora Maribel Jiménez Juárez de España. Hoy Maribel viene al podcast para hablarnos de los beneficios de viajar a España para hacer una inmersión en español.Temas que se mencionan en este episodio:Viajar a España baratoIr a España a estudiarViajar a España como estudiante Hacer una inmersión lingüística en españolViajar a España desde USA¡Descargá la transcripción de este episodio!Obtené ahora mismo la transcripción del episodio con fotos, un glosario y actividades de comprensión uniéndote a nuestro grupo de familia y amigos. Además, tendrás acceso a un episodio BONUS cada mes y muchos otros beneficios como clases conmigo. Unite a nuestra comunidad de Patreon y empezá a hablar español con confianza. Más información en este enlace. https://patreon.com/easyargentinespanish ¿Necesitás que te de una mano con tu español?Crear un Podcast es un laburo tremendo, es decir, me lleva mucho tiempo y dedicación. Si te unís a nuestra comunidad, nos ayudás a seguir motivados para crear más contenido. A cambio, yo también te doy una mano, es decir, te ayudo con tu español. Con tu colaboración accederás a contenido exclusivo para que hables español como un auténtico argentino. Más información en este enlace. https://patreon.com/easyargentinespanish Recursos que complementan este episodio:Datos de contacto de la profe Maribel: Instagram: @spanishconversationteacher Programa de inmersiónIf you've been feeling overwhelmed by fast paced Spanish speakers and you're finally ready to better understand spoken Spanish, then do yourself a favor and go to easyargentinespanish.com/video. I created this FREE 10-minute video lesson to make sure you know the 3 key features of Argentine pronunciation to better understand spoken Spanish. Support the showRECURSOS INDISPENSABLES PARA ESTUDIANTES DE ESPAÑOL Clase GRATIS de pronunciación rioplatense para entender mejor el español hablado. https://easyargentinespanish.com/video GUÍA GRATIS de Frases útiles que te ayudarán a hablar en español con confianza cuando converses con argentinos. Episodios BONUS, transcripciones, glosarios, actividades y clases conmigo, entre muchos otros beneficios: Más información en este enlace. Blog de Easy Argentine Spanish: easyargentinespanish.com/blog Ebook: Help! I Am Dating an Argentinian: The Ultimate Guide to Learn Argentine Spanish. #1 New Release on Amazon! APP de gramática VOS SOS app de Easy Argentine Spanish para practicar el uso del pronombre "vos" vs "tú".

How did we achieve nuclear fusion? Neil deGrasse Tyson and comedian Chuck Nice learn about thermonuclear fusion, the world's most powerful lasers, and harnessing nuclear power with operations manager at The National Ignition Facility, Bruno Van Wonterghem.NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free.Thanks to our Patrons Gavin Mallow, Willest74, Isaac Labbe, Allen, and Beefcake for supporting us this week.Photo Credit: U.S. Department of Energy from United States, Public domain, via Wikimedia Commons